Tapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis.

Bobonich, Margaret; Gorelick, Joe; Aldredge, Lakshi; Bruno, Matthew J; DiRuggiero, Douglas; Martin, George; Tallman, Anna M; Gold, Linda Stein

Bobonich, Margaret; Gorelick, Joe; Aldredge, Lakshi; Bruno, Matthew J; DiRuggiero, Douglas; Martin, George; Tallman, Anna M; Gold, Linda Stein.

J Drugs Dermatol ; 22(8): 779-784, 2023 Aug 01.

Article in En | MEDLINE | ID: mdl-37556512

Subject(s)

Dermatitis, Atopic; Psoriasis; Humans; Dermatitis, Atopic/drug therapy; Emollients/therapeutic use; Psoriasis/diagnosis; Psoriasis/drug therapy; Psoriasis/metabolism; Receptors, Aryl Hydrocarbon/agonists; Skin/metabolism; Treatment Outcome; Clinical Trials, Phase III as Topic; Randomized Controlled Trials as Topic

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Dermatitis, Atopic Type of study: Clinical_trials / Diagnostic_studies Limits: Humans Language: En Journal: J Drugs Dermatol Journal subject: DERMATOLOGIA Year: 2023 Type: Article

Fulltext

XML

PubMed Links

Search on Google